Hoersholm, Denmark, May 31th 2017
Hoersholm, Denmark, May 31th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that the first patient has entered the APO010 Phase 1/2 study for Multiple Myeloma (MM). APO010 is a first-in-class FAS- ligand anticancer product in immuno-oncology (“IO”). The DRPTM (Drug Response Predictor) Screening for sensitive patients with MM at four centers has been ongoing and >50 patients have already consented to have their tumor tissue DRP analyzed. In total 150 evaluable patients, will be screened using OV’s DRPTM with the aim to identify those Multiple Myeloma patients with the highest likelihood to benefit from treatment with APO010.